ObamaCare Could Have a Big Impact on the Market for Drugs. But Will It Be Positive or Negative?

Potential shortfalls in enrollment for President Barack Obama‘s health-care overhaul would put a 30 percent dent in projections for U.S. prescription-drug sales in 2017, a report from IMS Health Inc. shows.

That worst-case scenario would translate to $320 billion in drug spending, according to the report. The best case is supposed to be $460 billion, boosted by demand from the health law’s expansion of insurance coverage and medical screenings, and removal of restrictions on pre-existing conditions. (More)

Comments (12)

Trackback URL | Comments RSS Feed

  1. Buster says:

    ObamaCare has been giving me a headache for several years now. I wish I had invested in Bayer Aspirin.

    • Trent says:

      I would actually look into pharmaceutical investment, since preemptive care is so big right now, doctor’s may begin pumping out prescription medications.

  2. Perry says:

    Maybe you should invest in some Vicodin to get through the next few years.

  3. Trent says:

    “106,185 people enrolled in private health plans through insurance exchanges that debuted Oct. 1 as part of the Patient Protection and Affordable Care Act of 2010. U.S. health officials had a goal of enrolling 800,000 people through November and an estimated 7 million sign-ups were predicted for the first year.”

    Just a tad off the mark…

  4. Lucas says:

    “Still, global spending on drugs is projected to surpass $1 trillion in 2014 for the first time, and reach $1.2 trillion in 2017. The growth of as much as $235 billion from 2012 to 2017 would roughly match the $234 billion increase in the prior five years, according to the report.”

    Whether its legal or illegal, people want, and will get their drugs.